Lésions oculaires de l’onchocercose et observance au Traitement à L’Ivermectine Sous Directives Communautaires (TIDC).

Aim: The aim of our study was to determine whether the ocular complications of onchocerciasis influenced the compliance with CDTI. Materials and methods: We conducted a cross-sectional descriptive study including all subjects aged 10 years or more. . The variables studied were visual acuity, type of visual impairment, gender, onchocerciasis ocular manifestations, the number of time Ivermectin was taken over the last 5 years. Results: We recruited 764 patients or 1528 eyes. The number of eyes with ocular manifestations of onchocerciasis was 56 while the number of eyes without was 1472. We found a prevalence of 48% good adherence CDTI within the general population. Nevertheless the prevalence among cases was of 57% good compliance compared to a prevalence of 48% among controls (P = 0.28). This similarity in the pattern of taking Ivermectin between female and male was found. Conclusion : Patients with onchocerciasis ocular involvement showed better compliance to CDTI in the Littoral region. Gender is not a factor influencing compliance to CDTI in our study in contrast to some available reports in the literature. The pattern of taking Ivermectin is not a contributing factor predisposing male to onchocerciasis ocular involvement. In the absence of visual impairment, patients with onchocerciasis ocular involvement have better compliance to CDTI. : The presence of onchocerciasis ocular involvement seems to be a motivating factor to a better compliance to CDTI for affected patients. Keywords: Compliance, Onchocerciasis, Ivermectin , Cameroon Normal 0 21 false false false FR JA X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Tableau Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin-top:0cm; mso-para-margin-right:0cm; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0cm; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-fareast-language:EN-US;}